American Heart Journal
Volume 149, Issue 2 , Pages 240-253 , February 2005

Highlights from the American Heart Association Annual Scientific Sessions 2004: November 7-10, 2004

References 

  1. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 2002;346:877–883
  2. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann. Intern. Med. 2003;138:445–452
  3. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study (V-HeFT). N. Engl. J. Med. 1986;314:1547–1552
  4. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J. Card. Fail. 1999;5:178–187
  5. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 2004;351:2049–2057
  6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. (CONSENSUS) N. Engl. J. Med. 1987;316:1429–1435
  7. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581
  8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991;325:293–302
  9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N. Engl. J. Med. 1992;327:669–677
  10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828
  11. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 1995;333:1670–1676
  12. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000;342:145–153
  13. Fox KM EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators>. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial. (the EUROPA study) Lancet. 2003;362:782–788
  14. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA. 1996;276:889–897
  15. Steimle AE, Stevenson L, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–1172
  16. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51
  17. Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am. J. Cardiol. 1996;78:890–895
  18. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 1996;334:1349–1355
  19. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–1990
  20. Sodi-Pallares D, Disten A, Ponce de Leon J, et al. Polarizing solution in myocardial infarction. Am. J. Cardiol. 1968;21:275–276
  21. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 2001;345:1359–1367
  22. Landgraf JM, Abetz L, Ware JE. The CHQ User's Manual. Boston (Mass): Second Printing; 1999;[Health Act]
  23. Eicken A, Fratz S, Gutfried C, et al. Hearts late after Fontan operation have normal mass, normal volume and reduced systolic function. JACC. 2003;42:1061–1065
  24. van den Bosch AE, Roos-Hesselink JW, Van Domburg R, et al. Long-term outcome and quality of life in adult patients after the Fontan operation. Am. J. Cardiol. 2004;93:1141–1145
  25. Dunbar-Masterson C, Wypij D, Bellinger DC, et al. General health status of children with d-transposition of the great arteries after the arterial switch operation. Circulation. 2001;104(12, Suppl. I):I-138–I-142
  26. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90:1398–1403
  27. Boccara F, Cohen A. Interplay of diabetes and coronary heart disease on cardiovascular mortality. Heart. 2004;90:1371–1373
  28. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation. 2001;104:2767–2771
  29. Kong DF, Hasselblad V, Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am. J. Cardiol. 2003;92:651–655
  30. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 2004;350:232–238
  31. Mehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:
  32. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–1538
  33. Chartbook on Trends in the Health of Americans. U.S Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics, September 2003.
  34. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 2002;346:877–883
  35. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies. Eur. Heart J. 2000;21:2071–2078
  36. Connolly SJ, Schnell DJ, Page RL, et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am. J. Cardiol. 2001;88:974–979
  37. Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J. Am. Coll. Cardiol. 2004;43:39–43
  38. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 1986;8:1245–1255
  39. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;[published online November 10, 2004]
  40. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239

PII: S0002-8703(04)00880-4

doi: 10.1016/j.ahj.2004.12.001

American Heart Journal
Volume 149, Issue 2 , Pages 240-253 , February 2005

Article Tools